Therapeutic Effect of Dopamine Agonist ( Dopamine ) in Comparison with Oral Contraceptives in Reducing the Size of Ovarian Benign Tumors

Comparison of the Therapeutic effect of Oral Contraceptives with and without Dopamine Agonist ( Cabergoline ) in Reducing the Size of Ovarian Benign Tumors

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180815040802N1

Enrollment

Registered

2018-08-27

Start date

2018-08-06

Completion date

Unknown

Last updated

2018-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Ovarian Tumors. D27:Benign neoplasm of ovary

Interventions

Intervention 1: Intervention group: participants will receive 25 milligram Cabergoline ( dopamine agonist) tablets orally twice a week and Oral Contraceptives daily for 3 months. Intervention 2: Contr

using for 3 months.

Eligibility

Sex/Gender

Female

Age

15 Years to 49 Years

Inclusion criteria

Inclusion criteria: All women with Benign Ovarian Tumors in Reproductive Age

Exclusion criteria

Exclusion criteria: Hyperprolactinemia Hypercoagulability State Valvular Heart Disease

Design outcomes

Primary

Measure	Time frame
Size of benign ovarian tumor. Timepoint: measuring the size of tumor before intervention and after the 3 months; receiving drug. Method of measurement: Trans Vaginal Ultrasound.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKosar Aghajani

Tabriz University of Medical Sciences

Kosar_ani73@yahoo.com+98 41 3553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026